Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Werewolf Therapeutics Inc (HOWL)

Werewolf Therapeutics Inc (HOWL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,760
  • Shares Outstanding, K 48,540
  • Annual Sales, $ 1,890 K
  • Annual Income, $ -70,520 K
  • EBIT $ -72 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.74
  • Price/Sales 17.01
  • Price/Cash Flow N/A
  • Price/Book 1.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.62
  • Most Recent Earnings $-0.36 on 11/04/25
  • Next Earnings Date 03/10/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 294.73% (-139.04%)
  • Historical Volatility 166.28%
  • IV Percentile 55%
  • IV Rank 16.98%
  • IV High 1,118.91% on 04/10/25
  • IV Low 126.16% on 09/02/25
  • Expected Move (DTE 18) 0.9265 (149.44%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 5,719
  • Open Int (30-Day) 5,587
  • Expected Range 0.0000 to 1.5465

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.35
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.38
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +23.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5588 +10.95%
on 12/18/25
1.2000 -48.33%
on 12/17/25
-0.3800 (-38.00%)
since 11/28/25
3-Month
0.5588 +10.95%
on 12/18/25
2.2400 -72.32%
on 09/30/25
-1.5700 (-71.69%)
since 09/29/25
52-Week
0.5588 +10.95%
on 12/18/25
2.3800 -73.95%
on 09/29/25
-0.9300 (-60.00%)
since 12/27/24

Most Recent Stories

More News
Werewolf Therapeutics Announces Pipeline and Business Updates

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 –...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics Faces Nasdaq Compliance Challenge

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and...

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics to Participate in the BIO International Convention

HOWL : 0.6200 (-5.24%)
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

HOWL : 0.6200 (-5.24%)

Business Summary

Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.7100
2nd Resistance Point 0.6800
1st Resistance Point 0.6500
Last Price 0.6200
1st Support Level 0.5900
2nd Support Level 0.5600
3rd Support Level 0.5300

See More

52-Week High 2.3800
Fibonacci 61.8% 1.6843
Fibonacci 50% 1.4694
Fibonacci 38.2% 1.2545
Last Price 0.6200
52-Week Low 0.5588

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar